Orelabrutinib
- Product Name
- Orelabrutinib
- CAS No.
- 1655504-04-3
- Chemical Name
- Orelabrutinib
- Synonyms
- ICP-022;Orelabrutinib;Orelabrutinib USP/EP/BP;Orelabrutinib (ICP-022);6-(1-Acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide;:6-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)-3-Pyridinecarboxamide;3-Pyridinecarboxamide, 6-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)-;Malignancies,Btk,ICP 022,inhibit,antineoplastic,Inhibitor,chronic,small,Bruton tyrosine kinase,lymphocytic leukemia,cell,Orelabrutinib,ICP022
- CBNumber
- CB03369553
- Molecular Formula
- C26H25N3O3
- Formula Weight
- 427.49
- MOL File
- 1655504-04-3.mol
Orelabrutinib Property
- Boiling point:
- 646.3±55.0 °C(Predicted)
- Density
- 1.213±0.06 g/cm3(Predicted)
- pka
- 14.80±0.50(Predicted)
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
H315Causes skin irritation
H319Causes serious eye irritation
H335May cause respiratory irritation
- Precautionary statements
-
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
N-Bromosuccinimide Price
- Product number
- CS-0105163
- Product name
- Orelabrutinib
- Purity
- 98.93%
- Packaging
- 5mg
- Price
- $300
- Updated
- 2021/12/16
- Product number
- CS-0105163
- Product name
- Orelabrutinib
- Purity
- 98.93%
- Packaging
- 10mg
- Price
- $450
- Updated
- 2021/12/16
- Product number
- CS-0105163
- Product name
- Orelabrutinib
- Purity
- 98.93%
- Packaging
- 50mg
- Price
- $1200
- Updated
- 2021/12/16
- Product number
- CS-0105163
- Product name
- Orelabrutinib
- Purity
- 98.93%
- Packaging
- 100mg
- Price
- $1800
- Updated
- 2021/12/16
Orelabrutinib Chemical Properties,Usage,Production
Description
Orelabrutinib is a small molecule inhibitor of Bruton's tyrosine kinase with potential antineoplastic activity.
Uses
Orelabrutinib has been previously approved to treat patients with relapsed or refractory (R/R) mantle cell lymphoma and R/R chronic lymphocytic leukemia/small lymphocytic lymphoma.
Biological Activity
Orelabrutinib (ICP-022) is a potent, orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).
Mechanism of action
Upon administration, orelabrutinib binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK.
target
| Target | Value |
| BTK () |